Cost-Effectiveness Analysis of Delayed-Release Dimethyl-Fumarate In The Treatment of Relapsing-Remitting Multiple Sclerosis In Italy

Value in Health ◽

10.1016/j.jval.2015.09.2598 ◽

2015 ◽

Vol 18 (7) ◽

pp. A697 ◽

Author(s):

G Furneri ◽

L Santoni ◽

C Marchesi ◽

S Iannazzo ◽

P Cortesi ◽

...

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Dimethyl Fumarate ◽

Cost Effectiveness Analysis ◽

Delayed Release ◽

Effectiveness Analysis ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Cost-Effectiveness Analysis of Delayed-Release Dimethyl Fumarate for The Treatment of Relapsing Remitting Multiple Sclerosis In Spain

Value in Health ◽

10.1016/j.jval.2015.09.2931 ◽

2015 ◽

Vol 18 (7) ◽

pp. A755 ◽

Author(s):

D Gasche ◽

G Restovic ◽

V Casado ◽

P Ramírez-Boix ◽

J Martínez Lopez

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Dimethyl Fumarate ◽

Cost Effectiveness Analysis ◽

Delayed Release ◽

Effectiveness Analysis ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

PND24 COST-EFFECTIVENESS ANALYSIS OF DIMETHYL FUMARATE IN THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN ITALY

Value in Health ◽

10.1016/j.jval.2019.09.1794 ◽

2019 ◽

Vol 22 ◽

pp. S740-S741

Author(s):

L.G. Mantovani ◽

G. Furneri ◽

P.A. Cortesi ◽

E. Puma ◽

L. Santoni ◽

...

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Dimethyl Fumarate ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Cost-Effectiveness Analysis of Cladribine Tablets for Treatment of Patients with Relapsing-Remitting Multiple Sclerosis in Bulgaria

Value in Health ◽

10.1016/j.jval.2018.04.1403 ◽

2018 ◽

Vol 21 ◽

pp. S206 ◽

Author(s):

S Djambazov ◽

G Slavchev ◽

T Dineva ◽

P Panayotov ◽

T Vekov

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Cost-effectiveness analysis of escalating to natalizumab or switching among immunomodulators in relapsing-remitting multiple sclerosis in Italy

BMC Health Services Research ◽

10.1186/s12913-019-4264-1 ◽

2019 ◽

Vol 19 (1) ◽

Author(s):

Gianluca Furneri ◽

Laura Santoni ◽

Chiara Ricella ◽

Luca Prosperini

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

PND8 COST-EFFECTIVENESS ANALYSIS OF REBIF IN FIRST-LINE RELAPSING REMITTING MULTIPLE SCLEROSIS IN GERMANY

Value in Health ◽

10.1016/s1098-3015(10)66969-0 ◽

2008 ◽

Vol 11 (6) ◽

pp. A602

Author(s):

MJ Nuijten ◽

T Mittendorf ◽

A Jäcker ◽

U Osowski

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Cost-effectiveness analysis of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis

Journal of Medical Economics ◽

10.3111/200104207219 ◽

2001 ◽

Vol 4 (1-4) ◽

pp. 207-219 ◽

Author(s):

Uday Bose ◽

David Ladkani ◽

Anita Burrell ◽

Mohammad Sharief

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Glatiramer Acetate ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

PND2 TREATMENTS FOR HIGHLY ACTIVE RELAPSING REMITTING MULTIPLE SCLEROSIS: COST-EFFECTIVENESS ANALYSIS IN COLOMBIA

Value in Health Regional Issues ◽

10.1016/j.vhri.2019.08.332 ◽

2019 ◽

Vol 19 ◽

pp. S59

Author(s):

P. Lasalvia ◽

Y. Gil Rojas ◽

F. Hernández ◽

C. Castañeda-Cardona ◽

D. Rosselli

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

Highly Active ◽

Effectiveness Analysis ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Cost-Effectiveness Analysis of Peginterferon Beta-1a In The Treatment of Relapsing-Remitting Multiple Sclerosis In Scotland

Value in Health ◽

10.1016/j.jval.2015.09.2933 ◽

2015 ◽

Vol 18 (7) ◽

pp. A756

Author(s):

L Hernandez ◽

S Guo ◽

H Toro-Diaz ◽

S Carroll ◽

SF Syed Farooq

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Peginterferon beta-1a versus other self-injectable disease-modifying therapies in the treatment of relapsing-remitting multiple sclerosis in Scotland: a cost-effectiveness analysis

Journal of Medical Economics ◽

10.1080/13696998.2016.1247712 ◽

2016 ◽

Vol 20 (3) ◽

pp. 228-238 ◽

Author(s):

Luis Hernandez ◽

Shien Guo ◽

Hector Toro-Diaz ◽

Stuart Carroll ◽

Syed Feisal Syed Farooq

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis ◽

Disease Modifying Therapies ◽

Relapsing Remitting ◽

Disease Modifying ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Cost-Effectiveness Analysis of Peginterferon Beta-1a In The Treatment of Relapsing-Remitting Multiple Sclerosis In Ireland

Value in Health ◽

10.1016/j.jval.2015.09.2460 ◽

2015 ◽

Vol 18 (7) ◽

pp. A756

Author(s):

L Hernandez ◽

S Guo ◽

H Toro-Diaz ◽

S Carroll ◽

SF Syed Farooq

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text